IperionX gained after confirming its Virginia Titanium Manufacturing Campus is now operating 24/7. While the production ramp is a positive step, investors are watching the GenX platform closely as the key technology that could reshape its long-term titanium cost position.
IperionX (ASX:IPX) rose 4.66% to A$4.27 on Monday after its March 2026 quarterly report confirmed that the company's Virginia Titanium Manufacturing Campus is now running 24 hours a day, seven days a week. The plant has a nameplate capacity of around 200 tonnes per annum, with a much larger scale-up to 1,400 tonnes already underway. The 24/7 shift grabbed the headlines, but the more important story sits behind it. In parallel, IperionX is validating its next-generation GenX platform, the technology that will ultimately decide whether the company can claim the world's lowest titanium cost curve by 2030.
Today's Virginia output runs on IperionX's HAMR process, which produces titanium in batches. GenX is the next version of that technology, redesigned to run continuously rather than stop and start. That sounds technical, but the idea is simple. Continuous processing usually delivers far better unit economics than batch production, so if GenX is validated commercially, the long-term cost picture changes.
For context, titanium has been made using the Kroll process for roughly 80 years, a method known for being slow, energy-hungry and expensive. IperionX is aiming squarely at that cost barrier. The 24/7 milestone matters because it shows the Virginia team can run reliably enough to support that bigger transition.
In our view, the market is treating this news as a sign that execution risk on the Virginia ramp is fading. The larger re-rating catalyst, though, sits with GenX milestones expected later in 2026.
The funding position is unusually solid for a company at this stage. IperionX ended the March quarter with US$48.2 million in cash and still has US$42.1 million in obligated US Government reimbursements left to draw. Most of the roughly US$75 million cost of the planned expansion is already covered by a US$47.1 million US Department of Defense (DoD) award under its Industrial Base Analysis and Sustainment (IBAS) program. The government has also handed over around 290 tonnes of titanium scrap at no cost, enough to feed current production for about 1.5 years.
Customer demand is building alongside the funding. Early orders from defence contractors such as Carver Pump and American Rheinmetall, together with a US Army contract worth up to US$99 million over time, suggest buyers are starting to commit rather than just talk.
The bull case is clear. BTIG began coverage in March with a US$40 price target on IperionX's NASDAQ-listed shares. Because each of those US shares represents ten ASX shares, that target works out to roughly A$6 per ASX share, and it rests on IperionX capturing even a small slice of the large US titanium import market as defence supply chains move onshore.
The risks are just as real. A short-seller report from November 2025 still weighs on sentiment; GenX is not yet commercially proven, and the full expansion will not be commissioned until mid-2027. The shares also trade at a clear premium to speciality-metals peers, a premium that only holds if the 2026 milestones land on time.
For investors, the question is less about today's production headline and more about whether GenX can deliver the cost advantage management is promising.
To see which ASX resources and critical-minerals stocks ASR's analysts are watching now, download the free Top-3 Stocks & Market Outlook Report.
If you have any questions or feedback about our service, please feel free to contact us.
